...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program
【24h】

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program

机译:由国家骨髓捐献者计划促进成年受者无关捐献者造血细胞移植的二十年

获取原文
获取原文并翻译 | 示例

摘要

For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HIA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients. Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lym-phoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.
机译:20多年来,国家骨髓捐献者计划为成年接受者提供了无关的捐献者造血细胞移植服务。在此期间,全球的自愿捐助者池已扩展到近1200万,在HIA匹配的理解和技术方面已有所改善,临床实践和支持治疗发生了许多变化,更常见的移植物来源从骨髓(BM)转移到外周血干细胞(PBSC)。接受无关的供体移植的老年患者的百分比正在增加;目前,每10个成年移植受者中就有1个超过60岁。慢性粒细胞性白血病(CML)以前是不相关供体移植的最常见诊断,但是现在它仅占成人接受者移植的不到10%。急性骨髓性白血病(AML),急性淋巴细胞白血病(ALL),非霍奇金淋巴瘤(NHL)和骨髓增生异常综合征(MDS)的移植均超过CML。多年来,与治疗相关的死亡率(TRM)显着下降,尤其是与清髓性移植制备方案相关的死亡率。相应地,每个疾病类别中的存活率都有所提高。特别令人欣喜的是严重再生障碍性贫血(AA)的结果,其中2年生存率在短短10年内翻了一番。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号